Additionally, comparing to the high-risk subgroup, the low-risk subgroup had a higher mutation rate (20% vs. 13%) for PCLO which is frequently mutated in tumors, including hepatocellular carcinoma and diffuse large B-cell lymphoma [56,57]. The gene discussed is PCLO; the disease is hepatocellular carcinoma.